| abstract |
The present invention provides the use of the activity or expression level of Nuclear factor (erythroid -derived 2)-like 2 (NRF2)-activated genes products, e.g. SOD1 and CAT, in the prognosis of an OPA1 gene- or OPA1 gene product- deficit-induced disease, e.g. optic atrophy and optic neuropathy, or related complications by detecting expression or activity in a biological sample selected from fibroblasts, epithelial cells, blood samples or a mixture thereof, of a patient affected or suspected to be affected by said disease. |